Actelion is on track...
Message to Shareholders
Highlights
People
Addresses
Product Status
TracleerŽ - Worldwide Marketing
TracleerŽ - The Endothelin Receptor Antagonist
TracleerŽ - New hope for patients
Launch of ZavescaŽ
Development - Promising clinical data
Development - Addressing unmet medical needs
Drug Discovery Research
CFO's Letter
Corporate Governance
Consolidated Financial Statements - Report of the Group Auditors
Consolidated Financial Statements
Notes to the Consolidated Financial Statements
Holding Company Statements - Report of the Statutory Auditors
Holding Company Statements
Holding Company Statements - Notes to the Financial Statements
Shareholder Information
Actelion 2002
Products
Financial Statements
Products
THE ACTELION ANNUAL REPORT 2002
Product Status
TracleerŽ - Worldwide Marketing
TracleerŽ - The Endothelin Receptor Antagonist
TracleerŽ - New hope for patients
Launch of ZavescaŽ
Development - Promising clinical data
Development - Addressing unmet medical needs
Drug Discovery Research
Home
Contact
Actelion.com
Legal Disclaimer
